First drug OK'd for movement disorder

First drug OK'd for movement disorder


This photo provided by Neurocrine Biosciences, Inc. shows the label on a bottle of the drug Ingrezza. On Tuesday, April 11, 2017, the Food and Drug Administration approved Ingrezza, the first drug for treating a neurological syndrome that causes uncontrollable body movements that can also interfere with speech, swallowing and breathing.



from Biotech News